Publication
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine
| dc.contributor.author | Theys, K. | |
| dc.contributor.author | Camacho, R. J. | |
| dc.contributor.author | Gomes, P. | |
| dc.contributor.author | Vandamme, A. M. | |
| dc.contributor.author | Rhee, S. Y. | |
| dc.contributor.author | on behalf of the Portuguese HIV-1 Resistance Study Group | |
| dc.date.accessioned | 2016-09-28T09:15:00Z | |
| dc.date.available | 2016-09-28T09:15:00Z | |
| dc.date.issued | 2015-06 | |
| dc.description | This is an open access article under the CC BY-NC-ND license - http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.description.abstract | "Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its clinical benefit for HIV-1 infected patients failing first-generation NNRTIs is largely undefined. This study quantified the extent of genotypic rilpivirine resistance in viral isolates from 1212 patients upon failure of efavirenz- or nevirapine-containing antiretroviral treatment, of whom more than respectively 80% and 90% showed high-level genotypic resistance to the failing NNRTI. Of all study patients, 47% showed a rilpivirine resistance-associated mutation (RPV-RAM), whereas preserved residual rilpivirine activity was predicted in half of the patients by three genotypic drug resistance interpretation algorithms. An NNRTI-dependent impact on rilpivirine resistance was detected. Compared with the use of nevirapine, the use of efavirenz was associated with a 32% lower risk of having a RPV-RAM and a 50% lower risk of predicted reduced rilpivirine susceptibility. Most prevalent RPV-RAMs after nevirapine experience were Y181C and H221Y, whereas L100I+K103N, Y188L and K101E occurred most in efavirenz-experienced patients. Predicted rilpivirine activity was not affected by HIV-1 subtype, although frequency of individual mutations differed across subtypes. In conclusion, this genotypic resistance analysis strongly suggests that the latest NNRTI, rilpivirine, may retain activity in a large proportion of HIV-1 patients in whom resistance failed while they were on an efavirenz- or nevirapine-containing regimen, and may present an attractive option for second-line treatment given its good safety profile and dosing convenience. However, prospective clinical studies assessing the effectiveness of rilpivirine for NNRTI-experienced patients are warranted to validate knowledge derived from genotypic and phenotypic drug resistance studies." | pt_PT |
| dc.identifier.citation | Clin Microbiol Infect. 2015 Jun;21(6):607.e1-8. doi: 10.1016/j.cmi.2015.02.011 | pt_PT |
| dc.identifier.doi | 10.1016/j.cmi.2015.02.011 | pt_PT |
| dc.identifier.issn | 1198-743X | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/14893 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.relation | Collaborative HIV and Anti-HIV Drug Resistance Network | |
| dc.relation.publisherversion | http://dx.doi.org/10.1016/j.cmi.2015.02.011 | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Activity | pt_PT |
| dc.subject | HIV | pt_PT |
| dc.subject | Mutation | pt_PT |
| dc.subject | Resistance | pt_PT |
| dc.subject | Therapy | pt_PT |
| dc.title | Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Collaborative HIV and Anti-HIV Drug Resistance Network | |
| oaire.awardURI | info:eu-repo/grantAgreement/EC/FP7/223131/EU | |
| oaire.citation.endPage | 607.e8 | pt_PT |
| oaire.citation.startPage | 607.e1 | pt_PT |
| oaire.citation.title | Clinical Microbiology and Infection | pt_PT |
| oaire.citation.volume | 21(6) | pt_PT |
| oaire.fundingStream | FP7 | |
| project.funder.identifier | http://doi.org/10.13039/501100008530 | |
| project.funder.name | European Commission | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isProjectOfPublication | 8993c971-1d52-4f9f-857c-6e7a0f7fa1ee | |
| relation.isProjectOfPublication.latestForDiscovery | 8993c971-1d52-4f9f-857c-6e7a0f7fa1ee |